Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge  by Schutta, Christopher et al.
M
d
h
C
M
D
J
a
b
c
d
G
e
f
a
A
R
R
A
A
K
F
F
R
v
D
V
C
D
G
h
0Vaccine 34 (2016) 3214–3220
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
ultiple  efﬁcacy  studies  of  an  adenovirus-vectored  foot-and-mouth
isease  virus  serotype  A24  subunit  vaccine  in  cattle  using
omologous  challenge
hristopher  Schuttaa,  José  Barrerab,1,  Melia  Pisanob,c,1,  Laszlo  Zsaka,2,
arvin  J.  Grubmand, Gregory  A.  Mayrd,3, Mauro  P.  Moraesd,4,  Barbara  J.  Kamickere,
avid  A.  Brakee, Damodar  Ettyreddyf,  Douglas  E.  Broughf, Bryan  T.  Butmanf,
ohn  G.  Neilana,∗
Plum Island Animal Disease Center, U. S. Department of Homeland Security Science and Technology Directorate, P.O. Box 848, Greenport, NY 11944, USA
The McConnell Group, Inc., Plum Island Animal Disease Center, P.O. Box 848, Greenport, NY 11944, USA
Oak Ridge Institute for Science and Education, PIADC Research Participation Program, Oak Ridge, TN, USA
Plum Island Animal Disease Center, Foreign Animal Disease Research Unit, Agricultural Research Service, U. S. Department of Agriculture, P.O. Box 848,
reenport, NY 11944, USA
Leidos, Inc., Plum Island Animal Disease Center, P.O. Box 848, Greenport, NY 11944, USA
GenVec, Inc., 910 Clopper Road, Suite 220N, Gaithersburg, MD 20878, USA
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 1 September 2015
eceived in revised form 4 December 2015
ccepted 8 December 2015
vailable online 18 December 2015
eywords:
oot-and-mouth disease virus
MDV serotype A24 Cruzeiro
eplication-deﬁcient human adenovirus
ectored vaccine
IVA
accine efﬁcacy
a  b  s  t  r  a  c  t
The  safety  and  efﬁcacy  of  an  experimental,  replication-deﬁcient,  human  adenovirus-vectored  foot-and-
mouth  disease  virus  (FMDV)  serotype  A24 Cruzeiro  capsid-based  subunit  vaccine  (AdtA24)  was  examined
in eight  independent  cattle  studies.  AdtA24  non-adjuvanted  vaccine  was  administered  intramuscularly  to
a total  of 150  steers  in  doses  ranging  from  approximately  1.0  ×  108 to 2.1 ×  1011 particle  units per animal.
No detectable  local  or systemic  reactions  were  observed  after  vaccination.  At  7 days  post-vaccination
(dpv),  vaccinated  and  control  animals  were  challenged  with  FMDV  serotype  A24  Cruzeiro  via  the  intra-
dermal  lingual  route.  Vaccine  efﬁcacy  was  measured  by  FMDV  A24  serum  neutralizing  titers and  by
protection  from  clinical  disease  and  viremia  after challenge.  The  results  of  eight studies  demonstrated
a  strong  correlation  between  AdtA24  vaccine  dose  and  protection  from  clinical  disease  (R2 =  0.97)  and
viremia  (R2 = 0.98).  There  was  also  a strong  correlation  between  FMDV  A24  neutralization  titers on  day
of challenge  and protection  from  clinical  disease  (R2 = 0.99).  Vaccination  with  AdtA24  enabled  differ-
entiation  of  infected  from  vaccinated  animals  (DIVA)  as  demonstrated  by the  absence  of antibodies  to
the FMDV  nonstructural  proteins  in  vaccinates  prior  to  challenge.  Lack  of  AdtA24  vaccine  shedding  after
vaccination  was  indicated  by the  absence  of neutralizing  antibody  titers  to  both  the  adenovector  and
FMDV  A24  Cruzeiro  in  control  animals  after  co-mingling  with  vaccinated  cattle for three  to  four  weeks.
In  summary,  a non-adjuvanted  AdtA24  experimental  vaccine  was  shown  to be  safe,  immunogenic,  consis-
tently protected  cattle  at 7 dpv  against  direct,  homologous  FMDV  challenge,  and  enabled  differentiation
of  infected  from  vaccinated  cattle  prior  to challenge.Published  by Elsevier
Abbreviations: FMD, foot-and-mouth disease; FMDV, foot-and-mouth disease virus
ruzeiro  vaccine; DIVA, differentiate infected from vaccinated animals; PU, particle u
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. Introduction
Foot-and-mouth disease (FMD) is the most highly contagious
isease affecting livestock resulting in signiﬁcant adverse economic
mpact worldwide [1]. FMD  is caused by a Picornaviridae virus,
oot-and-mouth disease virus (FMDV). FMDV affects domestic and
ild-life cloven-hoofed ruminants as well as swine. Typical FMDV
linical signs, although age and species dependent, include fever
nd lesions on the mouth, hooves, and teats. Most susceptible ani-
als survive infection, but often exhibit decreased production due
o debilitation from the lesions. The FMDV infection pathways and
ost response in cattle are reviewed by Arzt et al. [2].
FMD  is enzootic in many developing countries in Asia and Africa,
nd periodic FMD  vaccination campaigns are often practiced to pre-
ent outbreaks or mitigate spread. Current FMD  serotype-speciﬁc
accines are made by growing live FMDV in cell culture, following
y chemical inactivation and puriﬁcation of 140S virions. Concerns
bout FMDV introduction into the United States have prompted
overnment research and development into producing next gen-
ration vaccines that can be manufactured in the United States.
Mayr et al. initially described the construction of an E1/E3 repli-
ation deﬁcient human adenovirus 5 (Ad5) recombinant virus that
xpressed the FMDV serotype A12 P1 capsid coding region, portions
f the nonstructural protein coding regions, and the 3C protease,
ssential for P1 polyprotein processing [3]. Moraes et al. produced a
imilar virus containing the capsid coding region of FMDV serotype
24 Cruzeiro (Ad5-A24) that conferred protection in swine [4]. In a
ubsequent swine study, de Avila Botton et al. showed that higher
d5-A24 doses resulted in a better clinical outcome, higher serum
ntiviral activity, no viremia, and lower amounts of FMDV in nasal
ecretions [5]. Cattle vaccinated with Ad5-A24 were also protected
gainst FMD  clinical disease following homologous challenge at one
eek post-vaccination [6].
Details of the construction of the adenovector E1, E3 deleted
ackbone (Adt) used in the studies reported herein have been
reviously described [7,8]. Additionally, a human cytomegalovirus
romoter was added to control expression of the target FMDV gene
assette. The FMD  vaccine used in our studies (AdtA24) is based on
he FMDV strain A24 Cruzeiro P1-2A capsid and serotype A12 3C
rotease cloned into a replication deﬁcient human adenovirus C,
erotype 5 vector [9].
Based on the working hypothesis that a lead vaccine candidate
nd method of production could be identiﬁed for transition to a
ull development regulatory program, we conducted eight inde-
endent AdtA24 vaccine safety and efﬁcacy studies using FMDV
24 Cruzeiro experimental challenge at one week post-vaccination.
he primary goals were prevention of FMD  clinical disease without
dverse effects. The study series started with initial proof-of-
oncept studies using a research restricted vaccine production
ethod and culminated with the identiﬁcation of a vaccine puriﬁ-
ation method that could be scaled up and used in a manufacturing
rocess and a vaccine dose that met  the requirements for advance-
ent to a regulatory-based product licensing program.
. Materials and methods
.1. Animals
Healthy Holstein cross-bred steers four to ten months of age and
60–260 kg were purchased from an Association for the Assess-
ent and Accreditation of Laboratory Animal Care accreditedivestock facility. Steers were acclimated and housed in the Plum
sland Animal Disease Center (PIADC) BSL-3Ag animal facility. Prior
o vaccination, steers were randomly allocated to treatment groups
nd allowed to freely co-mingle in assigned rooms throughout the4 (2016) 3214–3220 3215
duration of the study. Animal care and study protocols were in
accordance with the institutional guidelines of the PIADC Institu-
tional Animal Care and Use Committee.
3. Experimental AdtA24 vaccines
The AdtA24 vaccine vector was  constructed by GenVec, Inc.
(Gaithersburg, MD)  as summarized by Brake et al. [9] and grown
in the M2A  cell line in adherent ﬂasks, shaker ﬂasks, or biore-
actors. Following lysis of AdtA24-infected host cells, sequential
downstream puriﬁcation steps were used to prepare the four
experimental vaccines of varying purity used in these studies
as follows: (1) three cycles of centrifugation on cesium chlo-
ride (CsCl) gradients (research restricted method); (2) benzonase
treatment followed by clariﬁcation by centrifugation to produce
downstream fraction 3 (DS3); (3) DS3 puriﬁcation using ultraﬁltra-
tion/diaﬁltration to produce downstream fraction 5 (DS5); (4) DS5
puriﬁcation through anion exchange chromatography (Cipheron Q
Hyper-D) to produce downstream fraction 7 (DS7). For each vac-
cine lot, FMDV capsid expression and processing was conﬁrmed
by Western blot of transfected cell lysates using a VP2-speciﬁc
monoclonal antibody [10] (kindly provided by CFIA, Winnipeg,
Canada), and particle units (PU) were quantiﬁed [8]. AdtA24 prepa-
rations were stored at −80 ◦C. On the day of vaccination, thawed
vaccines were diluted with ﬁnal formulation buffer (FFB; Lonza,
Walkersville, MD)  to the ﬁnal target dose. For each study, base-
line serum samples from each animal were collected immediately
prior to vaccination (Day 0). Steers were inoculated intramuscu-
larly (IM) in the cleidooccipitalis muscle with a single 2 ml  injection
in the right side of the neck with either placebo (FFB alone or an
Adt.Null vector) or AdtA24 (Table 1). Individual blood samples were
collected weekly and used for serum virus neutralization tests or
plasma virus isolation. Steers were assessed for potential adverse
reactions, including core body temperature and observations of
overall gross physical and injection site reactions.
4. Challenge virus preparation and administration
FMDV serotype A24 Cruzeiro (SGD variant) (isolate originated
in Brazil, approximately 1950) challenge virus stock (1 × 106
bovine infectious dose 50% [BID50]/ml) was prepared following
one time passage in BHK-21 cell culture [11] and two  ampliﬁ-
cations in bovine tongue. For challenge, virus stock was diluted
1:40 in Dulbecco’s Modiﬁed Eagle Medium (DMEM) with 1% antibi-
otics/antimycotics to obtain the target titer, 5.6–6.0 log10 tissue
culture infective dose 50% (TCID50/ml), based on titration on a
porcine cell line highly permissive for FMDV, LF-BK [12], or LF-BK
V6, [13,14].
One week post-vaccination, steers were sedated with
0.22 mg/kg of xylazine IM in the hindquarter and challenged
via the intradermal lingual (IDL) route using a minor modiﬁcation
of the World Organisation for Animal Health (OIE) guidelines
[15]. FMDV challenge (1 × 104 BID50/0.4 ml)  was delivered by
inoculation of 0.1 ml  into each of four sites on the upper surface of
the tongue. Sedation was reversed by administering 2–4 mg/kg of
tolazoline intravenously.
5. Clinical observations
Individuals, through masked treatment allocation, performed
immunizations, clinical observations (lesions), and laboratory
assays (plasma virus isolation, plasma rRT-PCR, and virus neutral-
ization tests). We  assessed the presence or absence of FMD  clinical
disease in sedated steers at 3, 7, 10, and 14 dpc. We  noted FMD
clinical signs and lesions using the following criteria: negative, no
3216 C. Schutta et al. / Vaccine 34 (2016) 3214–3220
Table 1
Summary of eight independent AdtA24 vaccine efﬁcacy studies in which steers were challenged at 7 days post-vaccination with FMDV serotype A24 Cruzeiro.
Study no. AdtA24 dose (PU/steer)
and puriﬁcation
method
N % Protection
from clinical
disease
% Protection
against viremia
FMDV mean VNT (day of challenge) Ad5 mean VNT titer
(log10) ±S.D. (day of
challenge)% Positive steers (log10) ±S.D.
1 FFB 4 0 ND 0 0.6 ± 0.0 ND
2.1  × 1011 CsCl 7 100** ND 100** 1.7 ± 0.3** ND
2 FFB 7 14 0 0 0.6 ± 0.0 0.6 ± 0.0
1.0  × 1011 CsCl 7 100** 100** 100** 1.6 ± 0.3** 0.9 ± 0.3*
2.1 × 109 CsCl 7 57 71* 43 1.1 ± 0.6* 0.7 ± 0.2
1.0  × 108 CsCl 7 14 29 0 0.6 ± 0.0 0.6 ± 0.1
3 FFB 6 0 ND 0 0.6 ± 0.0 ND
4.2  × 1010 CsCl 5 60 ND 80* 1.1 ± 0.4* ND
4 FFB 4 0 0 0 0.6 ± 0.0 0.6 ± 0.0
5.0  × 1010 DS5 5 80* 80* 80* 1.4 ± 0.6* 1.3 ± 0.4**
1.3 × 1010 DS5 6 100** 100** 100** 1.6 ± 0.5** 1.2 ± 0.5*
3.1 × 109 DS5 5 20 80* 40 0.8 ± 0.3 0.9 ± 0.3*
5.0 × 1010 DS7 5 100** 80* 100* 1.5 ± 0.6* 1.1 ± 0.4*
1.3 × 1010 DS7 6 83* 100** 83** 1.1 ± 0.5* 1.0 ± 0.4*
3.1 × 109 DS7 5 60 80* 60 1.1 ± 0.5* 0.8 ± 0.2*
5 2.0 × 1010 Adt.Null 10 0 0 0 0.6 ± 0.0 1.2 ± 0.5
2.0  × 1010 DS5 10 90** 100** 50* 0.9 ± 0.4* 1.4 ± 0.5
1.0  × 1010 DS5 10 70** 100** 40 0.8 ± 0.2* 0.9 ± 0.4
5.0  × 109 DS5 10 70** 100** 10 0.7 ± 0.2 1.0 ± 0.3
6 FFB 2 0 0 0 0.6 ± 0.0 0.6 ± 0.0
6.0  × 109 DS5 11 82 100* 100* 1.5 ± 0.3** 0.7 ± 0.2*
7 FFB 10 0 0 0 0.6 ± 0.0 0.6 ± 0.0
5.7  × 109 DS5 20 55* 90** 65** 1.0 ± 0.4** 1.3 ± 0.4**
8 FFB 2 0 0 0 0.6 ± 0.0 0.6 ± 0.0
1.8  × 1010 DS3 6 67 83 67 1.3 ± 0.6* 0.7 ± 0.2
4.5  × 109 DS3 6 83 83 50 0.9 ± 0.5 0.7 ± 0.2
1.1  × 109 DS3 6 67 67 33 0.9 ± 0.5 0.6 ± 0.0
2.8  × 108 DS3 6 17 17 17 0.6 ± 0.1 0.8 ± 0.3
Total  vaccinates 150
Total controls 45
Different from the control group within a study:
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** P-value < 0.01.
edal or secondary (lip, mouth, or nose) vesicular lesions; positive,
ne or more pedal vesicular lesions on one or more feet or any
econdary vesicular lesions. For dose response studies using eco-
omically feasible puriﬁcation methods, we calculated the bovine
rotective dose for 50% or 80% of steers (BPD50 or BPD80) using the
pearman/Kärber method with endpoint generalized lesion data
btained on 14 dpc [16].
.1. Virus neutralization test (VNT)
FMDV serotype A24 strain Cruzeiro and adenovirus serotype
 (Ad5) antibody titers were determined using heat-inactivated
56 ◦C, 30 min) serum samples that were serially diluted four-fold
modiﬁed from 15). FMDV VNT titers were determined in duplicate
ells after 3 days in BHK-21 cell cultures grown on DMEM supple-
ented with 10% fetal bovine serum, 1% Modiﬁed Eagle Medium
on-essential amino acids (MEM NEAA), 1% MEM  with sodium
yruvate, 1% antibiotic/antimycotic, and 0.15% sodium bicarbon-
te. Ad5 VNT titers were determined in duplicate wells after 10
ays by a constant-virus decreasing-serum neutralization assay in
EK293 cells grown in MEM  supplemented with 3% fetal bovine
erum, 1% MEM  NEAA, 1% antibiotic/antimycotic.
FMDV and Ad5 VNT titers were calculated using the
pearman–Kärber method based on cytopathic effect (CPE) using
0% as the neutralization endpoint, and the lower limit of assay
etection was 0.6 log10 [17,18]. The geometric mean virus neutral-
zation test titers (GMT) were calculated using a value of 0.6 log10
or samples that were below the limit of detection. A test sam-
le was scored positive if the VNT titer was ≥0.9 log10, since more
oncentrated samples were not reliable in this assay.5.2. Detection of antibodies to FMDV non-structural protein (NSP)
The PrioCHECK® FMDV NS Antibody ELISA (ThermoFisher Sci-
entiﬁc) was used to detect antibodies to FMDV NSP according to
manufacturer’s instructions. A sample was  considered positive if
the percent inhibition was  ≥50%.
5.3. Detection of FMDV or FMDV nucleic acid
Plasma samples collected on 0 to 5 dpc were tested for the pres-
ence of viable FMDV [15]. Undiluted samples (20 l) were added
to single wells of 24-well plates containing BHK-21 or LF-BK cell
monolayers. A minimum of two  blind passages on CPE-negative
wells was conducted to conﬁrm the absence of infectious virus.
Plasma samples collected on 0 to 5 dpc were analyzed by Real-
Time Reverse Transcriptase–Polymerase Chain Reaction (rRT–PCR)
for the presence or absence of FMDV nucleic acid according to Calla-
han et al. [15,19]. A sample Ct value ≤40 was  scored as positive. Any
sample that was virus isolation or rRT–PCR positive during any of
the ﬁrst ﬁve dpc was scored as positive. In some instances, only one
assay method was  used on each sample collected.
5.4. Data analysis
VNT geometric means and standard deviations, and regression
analyses of both AdtA24 dose and protection from clinical disease
and viremia, as well as AdtA24 dose and VNT titer were con-
ducted (Microsoft Excel). Comparisons between the control group
and treatments groups within an experiment were done using the
two-tailed Fisher’s exact test (GraphPad). P-values ≤0.05 were con-
sidered signiﬁcant.
cine 34 (2016) 3214–3220 3217
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Fig. 1. FMDV virus neutralization test (VNT) and nonstructural protein (NSP) sero-
logical responses of steers immunized with AdtA24 (Efﬁcacy Study 6). Steers were
administered 6.0 × 109 particle units of AdtA24 (treatment group 2 [T2], n = 11) or
ﬁnal formulation buffer (FFB) (control treatment group [T1], n = 2). All steers were
challenged 7 days later with virulent FMDV serotype A24. The virus neutralization
test (VNT) titers for FMDV A24 were measured prior to vaccination and every 7 days
for 21 days and shown by the bars with geometric mean VNT titer (GMT) values on
the left vertical axis (±standard deviation; limit of detection range: >0.6–3.6 log10).C. Schutta et al. / Vac
. Results
.1. Safety
No adverse local or systemic reactions were observed during the
rst three days following AdtA24 IM administration to 150 steers.
. Efﬁcacy
.1. Response of control steers to FMDV serotype A24 Cruzeiro
nfection
Following challenge with FMDV serotype A24 Cruzeiro, 98%
44/45) of FFB- or Adt.Null-inoculated, control steers developed
edal lesions by 3 dpc. Viremia was detected as early as 1 dpc,
ith most animals positive on 2 and 3 dpc, and rarely on 4 dpc.
erum VNT (typically 2.4 to 3.0 log10) and NSP antibody responses
n control steers were detected on 7 and 14 dpc (data not shown).
.2. Vaccine efﬁcacy studies at 7 dpv
A summary of results and statistical comparisons from testing
dtA24 preparations puriﬁed by one of four methods and spanning
 2100-fold dose range in eight studies are summarized in Table 1.
etails are summarized below and grouped by AdtA24 puriﬁcation
ethod.
.3. CsCl preparation: efﬁcacy Studies 1, 2, and 3
In Efﬁcacy Study 1, the highest immunizing dose tested in all
ight studies, 2.1 × 1011PU/steer, prevented clinical disease in all
even steers and resulted in the highest VNT titer at the time of
hallenge (Table 1). In Efﬁcacy Study 2, we titrated three doses
hat spanned a 1000-fold range, and a clear dose-titration effect
ccurred in protection from clinical disease and viremia, and in the
NT titers and percent seropositive (Table 1). In Efﬁcacy Study 3,
 pilot study using 4.2 × 1010 PU/steer, was designed to evaluate
fﬁcacy at an earlier time point, 4 dpv, compared to 7 dpv. Despite
he absence of detectable VNT to FMDV A24 Cruzeiro, protection
gainst FMD  generalized disease was 60% in both the 4 and 7 dpv
roups (Table 1; data not shown for 4 dpv group).
.4. DS5 and DS7 preparations: efﬁcacy Studies 4, 5, 6, and 7
Efﬁcacy Study 4 was designed to determine if there were
ifferences in the efﬁcacy of two production scale-able vaccine
reparations, DS5 and DS7, tested with the identical three doses in
he same study (Table 1). The two highest doses were nearly indis-
inguishable for prevention of clinical disease and viremia, as well
s post-vaccination/pre-challenge geometric VNT titer. Although
he DS7 low dose preparation induced a stronger response than
n equivalent DS5 dose in terms of VNT titer and protection, the
alculated DS5 BPD50 (6.3 × 109 PU) and DS7 BPD50 (3.5 × 109 PU)
ere similar enough that we chose to conduct further studies on
he less puriﬁed preparation, DS5, which would be more economi-
al for commercial production. In Efﬁcacy Study 5, we examined
he effects of a high dose of the placebo vector, Adt.Null, and
nother dose titration of the DS5 preparation for comparison to
esults in Efﬁcacy Study 4. All Adt.Null-inoculated steers devel-
ped clinical disease and viremia following challenge (Table 1). For
he three AdtA24 treatment groups, there was a relatively ﬂat dose
esponse with respect to seroconversion and to efﬁcacy. All 30 vac-
inates were protected from viremia. The DS5 calculated BPD80 was
.1 × 109 PU, similar to the calculated BPD50 in Efﬁcacy Study 4. In
fﬁcacy Study 6, we tested an AdtA24 DS5 vaccine produced under
n experimental outline of production at an immunizing dose thatAntibody production to the FMDV NSP was measured weekly, and data are recorded
as lines with values on the right vertical axis. A positive response for antibodies to
the  FMDV NSP is indicated by ≥50%.
was slightly below the DS5 BPD80 value (7.1 × 109 PU) determined
in Efﬁcacy Study 5 (Table 1). All vaccinates were FMDV seroposi-
tive at 7 dpv, and 64% of these had VNT titers ≥1.5 log10. Following
challenge, 82% and 100% were protected against clinical disease
and viremia, respectively. In Efﬁcacy Study 7, the same AdtA24 DS5
experimental lot used in Efﬁcacy Study 6 was further evaluated
at an immunizing dose of 5.7 × 109 PU in two treatment groups
that were challenged at 7 dpv (Table 1) or 14 dpv. The GMT  (±
standard deviation) and percent VNT positive were higher at 14
dpv (1.3 ± 0.5 log10; 80%) compared to 7 dpv (1.0 ± 0.4 log10; 65%),
and clinical protection was higher in vaccinates challenged at 14
dpv (75%) compared to 7 dpv (55%).
7.5. DS3 preparation: efﬁcacy study 8
The goal of Efﬁcacy Study 8 was  to determine if the least puri-
ﬁed DS3 vaccine preparation had a similar BPD50 to the DS5 and
DS7 vaccines used in Efﬁcacy Study 3 (Table 1). Although the DS3
preparation had a lower BPD50 (1.4 × 109 PU)  compared to DS5 and
DS7 (Study 4), concerns related to assay consistency and long term
product stability associated with the vaccine potency release led to
a decision to not advance the DS3 production method.
7.6. Serological responses to FMDV and nonstructural proteins
In eight efﬁcacy studies, 66% (99/150) of AdtA24 vaccinates had
detectable FMDV neutralizing antibodies, but none of the vacci-
nates had antibodies to NSPs at the time of challenge. To illustrate
this point, in Efﬁcacy Study 6 at 7 dpv (day of challenge), all eleven
steers immunized with 6.0 × 109 PU of AdtA24 were VNT positive
and NSP negative (Fig. 1). At 7 and 14 dpc, all vaccinated and naive
steers were VNT and NSP seropositive.8. Discussion
This series of eight AdtA24 independent vaccine studies greatly
expands upon our previous proof-of-concept cattle experiment [6].
3218 C. Schutta et al. / Vaccine 34 (2016) 3214–3220
Fig. 2. Correlation between AdtA24 vaccine dose and cumulative protection from
clinical disease and viremia. Protection from clinical disease was evaluated in steers
vaccinated with one of 17 doses of AdtA24 and challenged at 7 dpv in eight studies.
Protection from viremia was evaluated in steers vaccinated with one of 15 doses in
six  studies. 69% (103/150) of vaccinates were protected from clinical disease, and
84% (116/138) were protected from viremia (Steers in two studies were not tested
for viremia.). The calculated dose for 50% and 90% prevention of clinical disease
were 1.0 × 1010 and 5.6 × 1010 PU/steer, respectively. The calculated dose for 50%
and 90% prevention of viremia were 8.0 × 109 and 3.0 × 1010 PU/steer, respectively.
The coefﬁcient of determination (R2) between cumulative percent protection from
clinical disease or viremia and the AdtA24 dose was calculated as R2 = 0.97 or 0.98,
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Fig. 3. Correlation between AdtA24 vaccine dose and the geometric mean virus neu-
tralization test titer (GMT). Steers were vaccinated with one of 17 doses of AdtA24
and challenged at 7 days post vaccination (dpv) in eight studies. Separate GMTs are
plotted for protected and not protected steers for each AdtA24 dose. The equations
describing the relationships between GMT  and AdtA24 dose for the protected and
large-scale manufacturing, several feasibility efﬁcacy studies were
conducted using material collected at different vaccine produc-
tion downstream steps. The DS3 preparation, at a 1.1 × 109 PU
Fig. 4. Protection from clinical disease of all 150 AdtA24 vaccinated steers chal-
lenged at 7 days post vaccination (dpv) in eight studies. The number of steersespectively, and the equations describing the relationships are on the graph.
he AdtA24 non-adjuvanted, IM-delivered vaccine was  safe over
he 2100-fold dose range evaluated as evidenced by an absence of
ocal or systemic untoward reactions. Additional safety of AdtA24
accine with respect to the absence of vaccine shed and spread
s inferred from the lack of FMD  VNT seroconversion in the co-
ingled, placebo controls.
Over the 1.0 × 108 to 2.1 × 1011 PU/steer dose range tested,
9% (103/150) of all Adt.A24 vaccinates were protected from clin-
cal disease. The best ﬁt curve for data correlating AdtA24 dose
ith cumulative percent protection from clinical disease had an
2 = 0.97 (Fig. 2). The estimated non-adjuvanted AdtA24 dose to
revent clinical disease in 50% or 90% of the protected steers was
.0 × 1010 PU/steer and 5.6 × 1010 PU/steer. Similarly, for the 116
accinated steers protected from viremia (84% of total), the best
t curve for data correlating vaccine dose with cumulative percent
rotection had an R2 = 0.98 (Fig. 2). The estimated AdtA24 dose to
revent viremia in 50% or 90% of steers was 8.0 × 109 PU/steer and
.0 × 1010 PU/steer.
The FMDV A24 Cruzeiro GMT  at time of challenge in protected
teers were not strongly correlated with vaccine dose (R2 = 0.51)
Fig. 3). This ﬁnding may  be due to the relatively short, one week
ime period between vaccination and challenge used in these
tudies compared to the OIE standard three week time interval
etween vaccination and challenge reported in most cattle potency
tudies using conventional, inactivated FMD  vaccines [15]. Other
ossible explanations for the lack of strong correlation may  be due
o the potency differences in the different vaccine preparations,
ealth status of the steers, cellular immune response differences,
r differences among individual steers in their antibody response
evels to FMDV A24 capsid proteins expressed by AdtA24-infected
ost cells. Importantly, on the day of challenge, 96% (63/66) of
accinates with VNT titers ≥1.2 log , and 87% (81/93) of vaccinates10
ith VNTs ≥0.9 log10 were protected from clinical disease (Fig. 4).
mong vaccinated, protected animals, the correlation between
ndividual VNT titers and cumulative protection from clinicalnot protected steers are on the graph. From the best-ﬁt line for protected steers, the
GMT  was  calculated as 1.6 log10 for 90% of the steers, and 1.2 log10 for 50% of the
steers.
disease was  R2 = 0.99 (Fig. 5). The predicted response for 50% and
90% cumulative protection from clinical disease at 7 dpv required
VNT titers of 1.0 log10 and 1.9 log10, respectively.
In a four study subset analysis in which at least 90% protection
against clinical disease was  observed, there was a poor correlation
(R2 = 0.22) between individual VNT titers to FMDV A24 Cruzeiro and
to Ad5 (data not shown). Although Ad5 seroconversion is indica-
tive of Adt.A24 vaccine exposure, these results suggest the low
feasibility of the future development of an Ad5-based antibody
assay as a surrogate correlation of protection at one week post-
vaccination.
Since CsCl puriﬁcation methods for AdtA24 are impractical forprotected and unprotected from clinical disease are displayed based on FMDV A24
VNT titer. For the 103 protected steers, the GMT  for 50% and 90% of the steers were
1.2 and 1.8 log10, respectively. For the 47 unprotected steers, the GMT for 50% and
90% were 0.6 and 0.9 log10, respectively.
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Fig. 5. For 103 steers protected from clinical disease, correlation between cumu-
lative protection from clinical disease and FMDV A24 geometric mean virus
neutralization test titer (GMT). Steers (n = 150) were vaccinated with one of 17 doses
of AdtA24 and challenged at 7 days post vaccination (dpv) in eight studies. The rela-
tionship between the GMT and cumulative protection from clinical disease for the
103 protected steers are presented along with the equation describing this relation-
ship. The calculated FMDV A24 GMT  titer to prevent clinical disease in 90% of the
103 steers that were protected from clinical disease was  1.9 log10 and for 50% of the
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[
PMID: 17109972. Epub 2006/11/18. eng. Jan 15].
[11] Mowat  GN, Brooksby JB, Pay TW.  Use of BHK 21 cells in the preparation ofteers, was  1.0 log10.
ose, protected at a similar level (67%) to that obtained with a
hree-fold higher DS5 dose (60%), and at a much higher level
ompared to a three-fold higher DS7 dose (20%). However, these
S3 results were obtained in a very limited number of animals
5–6/group), and in consideration of other important produc-
ion criteria (e.g., potency release testing and stability), the
dtA24 DS5 preparation was selected as the basis for future stud-
es.
None of the AdtA24 vaccinates were NSP positive prior to chal-
enge. This result is likely because the AdtA24 FMDV gene cassette
as designed to remove the FMDV 3A gene and the coding region
or the ﬁrst six amino acids of FMDV 3B which may  prevent anti-
ody inhibition in FMDV NS competitive ELISA. Although AdtA24
ncodes for the 3C protein, it is likely that the 3C protein is either
on-immunogenic in cattle following single dose administration
nd/or antibodies to the 3C protein are not inhibitory in the FMDV
S competitive ELISA. Thus, in addition to the manufacturing safety
spect of the Adt-based FMD  platform, another important feature
s its potential for use in a FMD  outbreak response in which a DIVA-
ased vaccination strategy may  be required. Additional studies
sing higher potency AdtA24 vaccines, prime-boost immunization
egimens, and serological testing at monthly time points will be
ecessary to validate and expand the encouraging DIVA results
btained in these pilot studies.
AdtA24 immunization 7 days prior to challenge with virulent
MDV serotype A24 Cruzeiro prevented clinical disease in 100%
f steers at doses ≥5.0 × 1010 PU. More recently, cattle efﬁcacy
tudies using adjuvant systems compatible with the Adt-based
MD  platform are very encouraging with respect to lowering the
dtA24 BPD50 and BPD80 vaccine dose (Schutta et al., manuscript in
reparation). Lastly, the relatively rapid onset of protection follow-
ng single dose immunization is another important aspect of the
dtA24 product proﬁle. The mechanism(s) of host protection fol-
owing single dose AdtA24 vaccine administration requires further
tudy and may  involve antibody-independent pathways or non-
eutralizing antibodies, since 24% (25/103) of the protected steers
ad undetectable VNT titers at time of challenge.4 (2016) 3214–3220 3219
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